cell culture uman gbm cell lines ln18  (ATCC)

Journal: RSC Medicinal Chemistry

Article Title: Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy

doi: 10.1039/d6md00227g

Figure Lengend Snippet: Evaluation of the effect of newly synthesized hybrids TC7, TC8, and TC9 (A–C), HO-1 inhibitors (D–F) and DASA (G) at different concentrations on GBM U87MG cell line viability following 48 h of treatment. Data are presented as mean ± SEM (*** p < 0.001 vs. control).

Article Snippet: Experiments were conducted on human GBM cell line U87MG (ATCC number HTB-14) (purchased from ATCC, Rockville, MD, USA).

Techniques: Synthesized, Control

Journal: RSC Medicinal Chemistry

Article Title: Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy

doi: 10.1039/d6md00227g

Figure Lengend Snippet: Effect of DASA, HO-1 inhibitors, combo, and codrug treatments (5 μM) on U87MG cell viability at 48 h. Data are presented as mean ± SEM. Statistical significances are reported in the figure.

Article Snippet: Experiments were conducted on human GBM cell line U87MG (ATCC number HTB-14) (purchased from ATCC, Rockville, MD, USA).

Techniques:

Journal: RSC Medicinal Chemistry

Article Title: Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy

doi: 10.1039/d6md00227g

Figure Lengend Snippet: (A and B) Evaluation of HO-1 enzymatic activity and protein expression levels in untreated (CTRL) and treated ( i.e. , 5 μM DASA, SI 1/09, and TC7) U87MG cells. (C) Evaluation of ROS level increase in U87MG cells after treatment with DASA, HO-1 inhibitors, combo, and codrugs at fixed concentrations (5 μM). (D) Measurement of intracellular thiol group (RSH) concentration following treatments (* p < 0.05, ** p < 0.005, *** p < 0.0005 vs. CTRL).

Article Snippet: Experiments were conducted on human GBM cell line U87MG (ATCC number HTB-14) (purchased from ATCC, Rockville, MD, USA).

Techniques: Activity Assay, Expressing, Concentration Assay

Journal: Chemical Biology & Drug Design

Article Title: Triazole‐Linked Pyrimidine Nucleoside Dimers: Design, Synthesis, and Applications in Medicinal and Nucleic Acid Chemistry. Part IV

doi: 10.1111/cbdd.70407

Figure Lengend Snippet: The expression of TYMS in diverse human cancers. The expression levels of TYMS in pan‐cancers were performed by GEPIA database. Red boxes – number of tumor samples ( T ). Gray boxes – number of normal samples ( N ). BRCA – breast invasive carcinoma ( T = 1085; N = 291). CESC – cervical squamous cell carcinoma and endocervical adenocarcinoma ( T = 306; N = 13). GBM – glioblastoma multiforme ( T = 163; N = 207). OV – ovarian serous cystadenocarcinoma ( T = 426; N = 88). * p < 0.05.

Article Snippet: GBM cell lines (U‐251 MG, U‐138 MG), SK‐OV‐3 (ovarian cancer cell line), HeLa (cervical cancer cell line), T47D (breast cancer cell line), and non‐cancerous lung fibroblast cell line (MRC‐5) were purchased from ATCC (Manassas, USA).

Techniques: Expressing

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Differential transduction of human GBM cell lines with AAV vector serotypes (A) Representative images of U-87 MG and patient-derived cell lines transduced with AAV1, 2, 1/2, 6, and 6.2 expressing eGFP and pBS control-treated control. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Quantitation of the transduction efficiency for all serotypes in each cell line as determined by GFP expression. All data presented as mean (SD), n = 3 biological replicates.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Plasmid Preparation, Derivative Assay, Expressing, Control, Staining, Quantitation Assay

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV transduced CD44-positive cell populations with greater efficiency (A) Transduction efficiency of AAV1, 2, 1/2, 6, and 6.2 in CD44-positive and -negative cell populations. Two-way ANOVA showed no significant interaction between the effects of AAV serotype and CD44 expression on transduction efficiency in all cell lines. There was a significant main effect of CD44 expression in U-87 MG ( p = 0.007), case 1 ( p = 0.0003), and case 4 ( p = 0.010) but no statistical significance was found following Sidak’s multiple comparisons test. (B) CD44 expression in human GBM cell lines following AAV treatment. (C) Proliferation of the CD44-positive cell population normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Expressing, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Reductions in cell number and proliferation following AAV treatment persisted in the absence of transgene expression (A) Representative images of U-87 MG, cases 2 and 5 transduced with AAV expressing eGFP or no transgene, along with their respective pBS controls. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Total cell number and (C) cell proliferation in the 24 h prior to fixation, normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Expressing, Transduction, Staining, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV treatment induced cell-cycle arrest at G1 in cases 2 and 5 but not U-87 MG (A) Cumulative cytotoxicity was evaluated by LDH release assay 4 days following AAV treatment, normalized to the maximal LDH release from the Triton X-100 control. No statistical significance was detected. (B) Percentage of cells in each cell cycle phase (G0/G1, S, and G2/M) were quantified via DNA content profiling (see also ). All data presented as mean (SD), n = 3 biological replicates. Treatments were compared against their respective pBS-treated control. Statistical significance is shown as G0/G1 phases: ∗∗∗∗ p < 0.0001; S phase: † p < 0.05; G2/M phases: # p < 0.05, ### p < 0.001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Lactate Dehydrogenase Assay, Control